DBP
Share:
Subscribe:
news.cision.com
/
DBP
/
Double Bond Pharmaceutical concludes Key Opinion Leader (KOL) meeting, an important milestone for SI-053 Phase 1 clinical study
/
M1 eng cut28092020
M1 eng cut28092020
Mon, Sep 28, 2020 17:00 CET
Low resolution
Medium resolution
Original resolution
Subscribe
